摘要
OBJECTIVE: To investigate the effect of the traditional Chinese herbs Astragali and Angelicae Sinensis(A & As) particle [contains Huangqi(Radix Astragali Mongolica), Danggui(Radix Angelicae Sinensis),Huzhanggeng(Rhizoma Polygoni Cuspidati) and Danshen(Radix Salviae Miltiorrhizae)] on proteinuria in glomerulonephritis patients with stage 2 chronic kidney disease.METHODS: A prospective, multi-center, and randomized controlled clinical trial was performed for 24 weeks. From March 2011 to April 2012, 158 patients from nine hospitals in China participated.They were randomized into the A&As group(79 cases, A&As particle 15.2 g/day) and losartan group(79 cases, losartan 50 mg/day). At each follow-up visit, clinical data including blood pressure, urinalysis, 24-h-urinary protein excretion, serum albumin and serum creatinine were collected.RESULTS: All 158 patients completed the follow-up. Proteinuria in the losartan group exhibited a biphasic time-dependent decline with a significant steady reduction from baseline to week 12(P = 0.0014), and a platform level during the remaining 12-week follow-up(P > 0.05). In contrast, there was a continual significant decrease of proteinuria in the A & As group(P < 0.001). When compared with the losartan results, proteinuria in the A & As group from week 16 to week 24 was significantly reduced(P < 0.001). Stable e GFRs and blood pressure were also observed in both groups. Medication side effects were minimal and non-fatal.CONCLUSION: For Chinese glomerulonephritis patients with stage 2 chronic kidney disease, therapy with A & As particles may provide effective anti-proteinuria treatment.
OBJECTIVE： To investigate the effect of the traditional Chinese herbs Astragali and Angelicae Sinensis（A As） particle [contains Huangqi（Radix Astragali Mongolica）, Danggui（Radix Angelicae Sinensis）,Huzhanggeng（Rhizoma Polygoni Cuspidati） and Danshen（Radix Salviae Miltiorrhizae）] on proteinuria in glomerulonephritis patients with stage 2 chronic kidney disease.METHODS： A prospective, multi-center, and randomized controlled clinical trial was performed for 24 weeks. From March 2011 to April 2012, 158 patients from nine hospitals in China participated.They were randomized into the AAs group（79 cases, AAs particle 15.2 g/day） and losartan group（79 cases, losartan 50 mg/day）. At each follow-up visit, clinical data including blood pressure, urinalysis, 24-h-urinary protein excretion, serum albumin and serum creatinine were collected.RESULTS： All 158 patients completed the follow-up. Proteinuria in the losartan group exhibited a biphasic time-dependent decline with a significant steady reduction from baseline to week 12（P = 0.0014）, and a platform level during the remaining 12-week follow-up（P 0.05）. In contrast, there was a continual significant decrease of proteinuria in the A As group（P 0.001）. When compared with the losartan results, proteinuria in the A As group from week 16 to week 24 was significantly reduced（P 0.001）. Stable e GFRs and blood pressure were also observed in both groups. Medication side effects were minimal and non-fatal.CONCLUSION： For Chinese glomerulonephritis patients with stage 2 chronic kidney disease, therapy with A As particles may provide effective anti-proteinuria treatment.
基金
Ministry of Scientific Technology of China Grant(Optimum Proposal of Traditional Chinese Medicine on Proteinuria in Patients with Primary Glomerulonephritis,No.201007005)
Shanghai Science&Technology Commission Grant(Clinical Study of Astragali Xiaobai Particle on Proteinuria in Patients with Primary Chronic Glomerulonephritis,No.14401972203)
Three Years of Development Project for Traditional Chinese Medicine of Shanghai Municipal Commission of Health and Family Planning(Senior Chinese Integrative Medicine Talent Cultivation Project,No.ZYSNXD012-RC-ZXY003)
Three Years of Development Project for Traditional Chinese Medicine of Shanghai Municipal Commission of Health and Family Planning(Effect of Astragali Xiaobai Particle on Proteinuria in Patients with Primary Chronic Glomerulonephritis,No.ZY3-JSFC-2-1029)
Innovative Research Team in Universities,Shanghai Municipal Education
